PBYI Q2 2025 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$52M+11.4% YoY

Gross Profit

$40M76.5% margin

Operating Income

$7M12.7% margin

Net Income

$6M11.2% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$195M

Total Liabilities

$90M

Stockholders' Equity

$105M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$52M	$47M	+11.4%
Gross Profit	$40M	$36M	+10.2%
Operating Income	$7M	-$2M	+404.5%
Net Income	$6M	-$5M	+229.3%

Revenue Segments

Product

$49M94%

Royalty

$3M6%